Screening for Type 1 Diabetes and Delaying Its Onset—An Innovative View

Release Date: December 22, 2025

Expiration Date: December 22, 2026

Activity Overview

The pathogenesis of type 1 diabetes (T1D) is now recognized to involve a progression of disease that advances through distinct stages prior to the onset of symptoms. With therapy now available to delay the onset of symptomatic T1D—and give the patient more time to prepare for managing the disease and potentially preserving a pool of residual β cells—primary care clinicians and endocrinologists must know how to identify at-risk patients and explain their treatment options. In this program, a panel of T1D experts explains how to efficiently screen patients and educate them on T1D-delaying therapy.

Target Audience

This educational initiative is directed toward endocrinologists, primary care providers, infusion nurses, nurse practitioners, physician assistants, and other health care professionals involved in the care of patients with T1D.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Summarize the differences in presentation and progression of onset of T1D in adults and children
• Identify relevant biomarkers used to assess risk of developing T1D or experiencing progressive disease
• Incorporate appropriate autoantibody testing to identify patients at risk of developing clinical T1D
• Evaluate clinical trial data for novel disease-modifying therapy for early-stage T1D